What's new? Log in Free sign up

Oculis Holding (OCS)

Company Profile

Company profile

Ticker

OCS, OCSAW

Exchange

Website

CEO

Dr. Riad Sherif M.B.A., M.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

OCS stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Current report (foreign)

Current report (foreign)

Notice of effectiveness

Prospectus supplement

Shelf registration (foreign)

Current report (foreign)

Current report (foreign)

Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

Current report (foreign)

Prospectus supplement for primary offering

Latest ownership filings

Pivotal bioVenture Partners Fund I, L.P.

Novartis Bioventures Ltd

Pivotal bioVenture Partners Fund I, L.P.

LSP 7 Cooperative UA

Brunnur vaxtarsjodur slhf

Pivotal bioVenture Partners Fund I, L.P.

Novartis Bioventures Ltd

Financial summary

Financial statements Chart OCS financial data

Quarter (USD)	Dec 23	Mar 23	Dec 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Mar 23	Dec 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2024

OCS institutional ownership history Ownership history

23.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	6	16	-62.5%
Opened positions	2	4	-50.0%
Closed positions	12	0	NEW
Increased positions	0	1	EXIT
Reduced positions	1	1	–

13F shares	Current	Prev Q	Change
Total value	149.07 mm	39.19 bn	-99.6%
Total shares	8.67 mm	12.94 mm	-33.0%
Total puts	0.00	0.00
Total calls	0.00	50.00 k	EXIT
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Brunnur vaxtarsjodur slhf	2.34 mm	$0.00	0.0%
Novartis Bioventures	2.18 mm	$0.00	0.0%
BVCF Iv	2.07 mm	$0.00	0.0%
Pivotal bioVenture Partners Fund I	2.03 mm	$34.90 mm	-33.0%
Calamos Advisors	33.33 k	$76.67 mm	NEW
Wolverine Asset Management	17.86 k	$37.51 mm	NEW
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
Pivotal bioVenture Partners Investment Advisor	0.00	-1.60 mm	EXIT
Standard Life Aberdeen	0.00	-1.10 mm	EXIT
Pivotal bioVenture Partners Fund I	2.03 mm	-1.00 mm	-33.0%
Nan Fung	0.00	-436.38 k	EXIT
Compagnie Lombard Odier SCmA	0.00	-95.75 k	EXIT
ExodusPoint Capital Management	0.00	-50.37 k	EXIT
Calamos Advisors	33.33 k	+33.33 k	NEW
Wolverine Asset Management	17.86 k	+17.86 k	NEW
BAC Bank of America	0.00	-17.16 k	EXIT
UBS UBS	0.00	-16.50 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $30 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $30 price target.

Oculis Holding Q3 2024 Adj. EPS CHF(0.48) Beats CHF(0.49) Estimate, Cash Balance Of CHF105.5M

Oculis Holding (NASDAQ:OCS) reported quarterly losses of CHF(0.48) per share which beat the analyst consensus estimate of CHF(0.49) by 2.04 percent.

HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $30 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $30 price target.

Oculis Expands DIAMOND Program with Global Retina Experts, Accelerating Phase 3 Trials for DME Treatment

Oculis Showcases Results for Diabetic Eye Treatment at Innovate Retina and Eyecelerator 2024

Press releases

From Benzinga Pro

Oculis to Present at the Stifel 2024 Healthcare Conference

ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis'

Oculis Reports Q3 2024 Financial Results and Provides Company Updates

Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial in acute optic neuritis (AON) with topline readout anticipated in December

Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees

Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentumDIAMOND program committees expanded with globally renowned retina experts If approved, OCS-01 has

Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.